共 30 条
- [21] FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple MyelomaBLOOD, 2022, 140 : 4560 - 4561Reiser, JohnChan, Szeman RubyMathavan, KetanSillitti, DavidMottershead, CristinaMattson, BethanyPache, MelissandreGutierrez, AlmaScoon, WhitneyZhu, YanniGilder, AndrewChen, ChristineStaquet, KimberlyPorts, MichaelDrake, CharlesErhardt, JosephBjordahl, RyanGoodridge, Jode P.Valamehr, Bahram
- [22] Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatinJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07)Zheng, LiuhaiWang, HuifangZhou, JihaoShi, GuangweiMa, JingboJiang, YukeDong, ZhiyuLi, JiexuanHe, Yuan-QiaoWu, DinglanSun, JichaoXu, ChengchaoLi, ZhijieWang, Jigang
- [23] Preclinical development of SENTI-202, an off-the-shelf logic gated CAR-NK cell therapy, for the treatment of CD33/FLT3+hematologic malignancies including AMLCANCER RESEARCH, 2023, 83 (07)Gonzalez, AlbaHong, EnpingYucel, GozdeLeitner, ElizabethChinta, PearleyDeng, HanLi, IanLam, AliceBakir, AblaLee, BrandonChakraborty, PapiaBlanco, CarminaLee, Chen-TingAlmudhfar, NiranTian, MengxiSong, WenqiBanicki, AndrewContreras, OttoGieldin, MartinGarrison, BrianLu, Timothy K.Rajangam, Kanya
- [24] NKX101, an allogeneic off-the-shelf NKG2D CAR-NK cell therapy, has potent in vitro cytotoxicity against patient-derived AML leukemic stem cells and non-leukemic stem cell blastsCANCER RESEARCH, 2024, 84 (06)Hansen, KyleCho, CynthiaKothari, NishiShook, DavidTrager, James
- [25] The "off-the-shelf "CD19-CAR-V δ 1T cells demonstrated an enhanced therapeutic effect on B-cell malignancy modelsCANCER RESEARCH, 2024, 84 (06)Chen, DanYou, FengtaoChen, ChengZhang, PingWu, HaiZheng, ZhongWang, MinWang, XingbingMeng, HuiminYang, NanZhang, BozhenYang, Lin
- [26] Senti-202, a Selective, Off-the-Shelf, Preclinical CAR-NK Cell Therapy with CD33 and/or FLT3 Activating CAR, Healthy Cell Protection from Endomucin (EMCN) Inhibitory CAR and Calibrated Release IL-15 for Hematologic Malignancies Including AMLBLOOD, 2022, 140 : 4531 - 4532Garrison, BrianDeng, HanYucel, GozdeFrankel, Nicholas W.Gordley, RussellHung, MichelleLee, DerrickGainer, MarcusRoguev, AssenGorman, WesleyLeemans, NeliaLam, AliceLi, YongshuaiWong, WilsonRajangam, Kanya L.Lee, PhilipLu, Tim
- [27] NKX101, an Allogeneic Off-the-Shelf CAR NK Cell Therapy Targeting NKG2D-Ls, Has Potent Anti-Leukemic Activity Alone or in Combination with Ara-CBLOOD, 2023, 142Cho, CynthiaHansen, KyleKimura, NikkiSood, JessicaJuat, DamieGeng, TaoTrager, James
- [28] NKX101, an allogeneic off-the-shelf CAR NK cell therapy targeting NKG2D-Ls, has potent anti-leukemic activity alone or in combination with Ara-CCANCER RESEARCH, 2024, 84 (06)Cho, CynthiaKimura, NikkiSood, JessicaJuat, DamieZhang, MaxChan, CarmelGeng, TaoHansen, KyleTrager, James
- [29] FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple MyelomaBLOOD, 2020, 136Goodridge, Jode P.Bjordahl, RyanMahmood, SajidReiser, JohnGaidarova, SvetlanaBlum, RobertCichocki, FrankChu, Hui-yiBonello, GregLee, TomGroff, BrianMeza, MiguelChu, Yu-WayeWalcheck, BruceMalmberg, Karl-JohanMiller, Jeffrey S.Rehm, ArminHopken, UtaValamehr, Bahram
- [30] NKX101, an Allogeneic Off-the-Shelf CAR NK Therapy Targeting NKG2D-Ls, Has Potent In Vitro Cytotoxicity Against Patient-Derived AML Leukemic Stem Cell (LSC) and Non-Leukemic Stem Cell (Non-LSC) BlastsBLOOD, 2023, 142Hansen, KyleCho, CynthiaMehta, NishiShook, DavidTrager, James